Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary protein technology that selectively modulates gene targets in disease tissues. This approach aims to enhance therapeutic efficacy and safety for complex diseases that have been difficult to treat with conventional methods.
Funding
$131.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases are difficult to treat effectively due to the challenge of delivering drugs specifically to the affected tissues, leading to systemic side effects and reduced therapeutic efficacy. Conventional methods often lack the precision needed to modulate gene targets selectively in disease tissues.
Solution
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary protein technology designed to selectively modulate gene targets within disease tissues. Centyrins are engineered to bind to specific receptors on target cells, enabling precise delivery of therapeutic oligonucleotides. By conjugating Centyrins to RNA drugs, Aro aims to enhance therapeutic efficacy and safety, addressing complex diseases that have been challenging to treat with traditional approaches. This targeted approach minimizes off-target effects and maximizes the impact of the genetic medicine at the site of disease.
Target Audience
The primary target audience includes patients with complex diseases that are difficult to treat with conventional methods, as well as pharmaceutical companies seeking to enhance the tissue-specificity of their therapeutics.
Features
- Centyrin platform for tissue-specific targeting of therapeutics
- Receptor-specific Centyrins that bind to target cells
- Conjugation of Centyrins to oligonucleotides for precise gene modulation
- Development of a wholly-owned pipeline of Centyrin-RNA drug conjugates
- Partnered pipeline leveraging Centyrins for tissue-specific drug delivery